clinical trial · NCT05718557
Study of PYX-106 in Solid Tumors
Solid TumorPYX-106
brief summary
The primary objective of this study is to determine the recommended dose(s) of PYX-106 in participants with relapsed/refractory solid tumors.
started
May 23, 2023
primary completion
May 1, 2026
completion
May 1, 2026
last updated
Aug 3, 2025
official title
A First-in-Human, Open-label, Multicenter, Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PYX-106 in Subjects With Advanced Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol